ZIOPHARM to Present at the 6th Annual Needham Biotechnology & Medical Technology Conference
Posted on: Thursday, 7 June 2007, 09:00 CDT
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the 6th Annual Needham Biotechnology & Medical Technology Conference on Thursday, June 14, 2007 at 1:30 p.m. ET at the New York Palace Hotel, New York. Dr. Lewis will provide an overview of the Company and an update on its clinical development programs.
The presentation will be webcast live and can be accessed by visiting the Investor Relations section at www.ziopharm.com. The webcast will be archived for ninety days.
About ZIOPHARM Oncology, Inc.
ZIOPHARM Oncology, Inc. applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.
ZIOP-G
Source: Business Wire
Related Articles
- Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse
- Goodyear Highlights Industry Challenges, Resulting Production Cuts at JP Morgan Investor Conference
- Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
- What to Look for When Your Candidates Go Green
- Statement From the Consumer Healthcare Products Association on the SAMHSA Findings on Cough Medicine Abuse
- Statement From the Consumer Healthcare Products Association on Today's FDA Advisory Committee Meeting on the Efficacy of Phenylephrine in the 10 Mg Oral Dose
- Dana-Farber/Harvard Cancer Center Implements Phase Forward's Electronic Data Capture Product for Pediatric Leukemia Study
- ZIOPHARM Presents Preliminary ZIO-201 Clinical Results at ASCO
- ARIAD Reports Fourth Quarter and Year-End 2005 Results; Product Development Goals and Financial Guidance for 2006 Provided
- Should Diabetes Be Considered a Coronary Heart Disease Risk Equivalent? Results From 25 Years of Follow-Up in the Renfrew and Paisley Survey
 |
 |
User Comments (0)
RSS Feeds